Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL14579837 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7464 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL12831358 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543836 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1593740 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL3265792 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL5318670 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL11984200 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL57495 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL57496 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039742-A1 | EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH | UNIVERSITE JOSEPH FOURIER - GRENOBLE 1 (FR) | 2016-02-11 | — | — | US | claimed |
| US-20140296262-A1 | Method to Treat Premature Ejaculation in Humans | TRINITY LABORATORIES, INC. (US) | 2014-10-02 | — | — | US | claimed |
| US-20100120780-A1 | TREATMENTS FOR PREMATURE EJACULATION IN HUMANS | TRINITY LABORATORIES INC. | 2010-05-13 | — | — | US | claimed |
| US-7470816-B2 | Tramadol recovery process | IPAC LABORATORIES LIMITED (IN) | 2008-12-30 | — | — | US | claimed |
| EP-1363872-B1 | METHOD FOR ISOLATING AND PURIFYING (1RS,2RS)-2- (DIMETHYLAMINO)METHYL -1-(3-METHOXYPHENYL)-CYCLOHEXANOL | GRUENENTHAL GMBH (DE) | 2008-08-20 | — | — | EP | claimed |
| US-20080176873-A1 | Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria | TRINITY LABORATORIES, INC. (US) | 2008-07-24 | — | — | US | claimed |
| US-20080058362-A1 | Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy | JEFFERSON BANK | 2008-03-06 | — | — | US | claimed |
| US-6909017-B2 | Method for isolating and purifying (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | GRUNENTHAL GMBH (DE) | 2005-06-21 | — | — | US | claimed |
| EP-1210118-B1 | COMPOSITION COMPRISING A TRAMADOL MATERIAL AND AN ANTICONVULSANT DRUG | ORTHO MCNEIL PHARM INC (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040225154-A1 | Method for isolating and purifying (1RS,2RS)-2-[ (dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| EP-1363872-A1 | METHOD FOR ISOLATING AND PURIFYING (1RS,2RS)-2- (DIMETHYLAMINO)METHYL]-1-(3-METHOXYPHENYL)-CYCLOHEXANOL | Grünenthal GmbH (DE) | 2003-11-26 | — | — | EP | claimed |
| US-6562865-B1 | Pharmaceutical composition comprising a synergistic combination of a tramadol material and topiramate, wherein the tramadol material and topiramate are present in a ratio based on a fraction of their respective ED50 values | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-13 | — | — | US | claimed |
| WO-2002066414-A1 | METHOD FOR ISOLATING AND PURIFYING (1RS,2RS)-2-[(DIMETHYLAMINO)METHYL]-1-(3-METHOXYPHENYL)-CYCLOHEXANOL | Grünenthal GmbH (DE) | 2002-08-29 | — | — | WO | claimed |
| EP-1210118-A2 | COMPOSITION COMPRISING A TRAMADOL MATERIAL AND AN ANTICONVULSANT DRUG | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001013904-A2 | COMPOSITION COMPRISING A TRAMADOL MATERIAL AND AN ANTICONVULSANT DRUG | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| JP-6157301-A | — | — | None | — | — | JP | disclosed |
| JP-6107540-A | — | — | None | — | — | JP | disclosed |
| EP-0009076-B1 | METHOD FOR THE QUANTITATIVE ENZYMATIC DETERMINATION OF ADP AND REAGENT FOR THIS METHOD | Roche Diagnostics GmbH (DE) | 1981-07-29 | — | — | EP | disclosed |
| EP-0009076-A1 | Method for the quantitative enzymatic determination of ADP and reagent for this method | Roche Diagnostics GmbH (DE) | 1980-04-02 | — | — | EP | disclosed |
| EP-0008342-A1 | Method and reagent for the determination of glutamic oxalacetic transaminase and glutamic pyruvic transaminase | Roche Diagnostics GmbH (DE) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225154-A1 | Method for isolating and purifying (1RS,2RS)-2-[ (dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | MRPS27, MAN1B1, MCRS1 | OPRM1 470/4885SLC6A2 2496/4885SLC6A4 2629/4885 |
| US-20160039742-A1 | EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885SLC6A2 15/4885SLC6A4 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.